Journal of cardiac failure, 2016-06, Vol.22 (6), p.439-448
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Heart Failure Therapies for End Stage Chemotherapy Induced Cardiomyopathy
- Ist Teil von
- Journal of cardiac failure, 2016-06, Vol.22 (6), p.439-448
- Ort / Verlag
- United States: Elsevier Inc
- Erscheinungsjahr
- 2016
- Quelle
- ScienceDirect
- Beschreibungen/Notizen
- Highlights • The incidence of chemotherapy induced cardiomyopathy (CCMP) will rise with an increasing cancer survivor population. • Limited studies of beta blockers and angiotensin converting enzyme inhibitor agents have suggested benefit in CCMP. • Small studies have shown benefit of cardiac resynchronization therapy in CCMP who meet guideline based indications. • CCMP patients requiring left ventricular assist device therapy have a higher incidence of right ventricular dysfunction. • CCMP patients undergoing orthotopic heart transplantation have similar survival outcomes compared to other nonischemic controls.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1071-9164eISSN: 1532-8414DOI: 10.1016/j.cardfail.2016.04.009Titel-ID: cdi_proquest_miscellaneous_1794122696
- Format
- –
- Schlagworte
- Adrenergic beta-Antagonists - therapeutic use, Angiotensin-Converting Enzyme Inhibitors - therapeutic use, anthracycline, Antineoplastic Agents - adverse effects, cardiac resynchronization therapy, Cardio-oncology, Cardiomyopathies - chemically induced, Cardiomyopathies - complications, Cardiomyopathies - therapy, cardiotoxicity, Cardiovascular, chemotherapy, chemotherapy induced cardiomyopathy, Heart Failure - etiology, Heart Failure - therapy, Heart Transplantation, Heart-Assist Devices, Humans, mechanical circulatory support, Neoplasms - drug therapy, Registries, trastuzumab, tyrosine kinase inhibitors